COMPANY

Calico

HQ: South San Francisco, CA source · calicolabs.com ↗ · West Coast

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Advanced Solid Tumor Cancer Autosomal Dominant Polycystic Kidney Disease Vanishing White Matter Disease ABBV-CLS-628 Fosigotifator ABBV-CLS-484 DRUG: ABBV-CLS-484

8Trials (company is sponsor)

Timeline

May 21, 2026 Partnership Partnership / licensing announced May 21, 2026. Source: company's own press page. source ↗
Jun 26, 2025 Partnership Partnership / licensing announced Jun 26, 2025. Source: company's own press page. source ↗
Jun 9, 2025 Trial start Phase 2: ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) source ↗
May 21, 2024 Trial start Phase 1: Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration source ↗
Mar 14, 2024 Trial start Phase 1: A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects source ↗
Dec 19, 2023 Trial start 1: A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262 source ↗
Mar 24, 2023 Trial start 1: A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects source ↗
Mar 13, 2023 Trial start Phase 1/Phase 2: An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease source ↗
Mar 9, 2021 Trial start Phase 1: Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors source ↗

Upcoming milestones

2026-10 (ESTIMATED) · Phase 1 · Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors · NCT04777994
2027-11 (ESTIMATED) · Phase 1/Phase 2 · An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease · NCT05757141
2029-08 (ESTIMATED) · Phase 2 · ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) · NCT06902558

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

May 21, 2026 Partnership / licensing announced May 21, 2026. Source: company's own press page. source ↗
Jun 26, 2025 Partnership / licensing announced Jun 26, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06902558	ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Phase 2	Recruiting	Jun 9, 2025	2029-08 (estimated)
NCT05757141	An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease	Phase 1/Phase 2	Recruiting	Mar 13, 2023	2027-11 (estimated)
NCT04777994	Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors	Phase 1	Recruiting	Mar 9, 2021	2026-10 (estimated)
NCT06425003	Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration	Phase 1	Completed	May 21, 2024	Jul 12, 2024 (actual)
NCT06310876	A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects	Phase 1	Completed	Mar 14, 2024	May 29, 2024 (actual)
NCT06145607	A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262	1	Completed	Dec 19, 2023	Jan 30, 2024 (actual)
NCT06188975	Expanded Access to ABBV-CLS-484	Not listed	Available	Not listed	Not listed
NCT05763459	A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects	1	Completed	Mar 24, 2023	May 8, 2023 (actual)